Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04502030 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) | completed | Phase 3 | 247 | OctapharmaINDUSTRY | 12 | Jun 4, 2026 | clinicaltrials |
| NCT00534430 | Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | completed | Phase 2 | 30 | City of Hope Medical CenterOTHER | 0 |
| Jun 3, 2026 |
| clinicaltrials |
| NCT03196830 | CAR-T for R/R B-NHL | completed | Phase 2 | 168 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04339400 | A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms | completed | Phase 1 | 79 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04923789 | A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma | completed | — | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06224309 | Preliminary Assessment of [18F]BL40 in PET/CT Scans | completed | — | 10 | British Columbia Cancer AgencyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT01371981 | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 1,645 | National Cancer Institute (NCI)NIH | 5 | Jun 2, 2026 | clinicaltrials |
| NCT02651662 | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies(CLIO-1) | completed | Phase 1 | 105 | Regeneron PharmaceuticalsINDUSTRY | 6 | Jun 2, 2026 | clinicaltrials |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | completed | Phase 3 | 5,949 | National Cancer Institute (NCI)NIH | 7 | Jun 2, 2026 | clinicaltrials |
| NCT03652064 | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | completed | Phase 3 | 395 | Janssen Research & Development, LLCINDUSTRY | 13 | Jun 2, 2026 | clinicaltrials |
| NCT04539444 | A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma | completed | Phase 2 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05322330 | Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT00085124 | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 500 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04552288 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04600804 | The Role of 18F-FDG-PET for Staging and Prognostication | completed | — | 200 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Jun 1, 2026 | clinicaltrials |
| NCT05162170 | Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study | completed | — | 633 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06113081 | Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma(FIL_MOGA) | completed | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07616635 | A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia (FOVOCIP)(FOVOCIP) | completed | Phase 3 | 177 | Fundación para la Investigación Biosanitaria del Principado de AsturiasOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02583893 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02688140 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia(TUD-APOLLO-064) | completed | Phase 3 | 133 | Technische Universität DresdenOTHER | 5 | May 29, 2026 | clinicaltrials |
| NCT05296096 | PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS(PROXIMUS) | completed | N/A | 18 | Boston Children's HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07614243 | Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral Neuropathy(ZFAS1-BIPN) | completed | N/A | 22 | The First Affiliated Hospital of Zhejiang Chinese Medical UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | completed | Phase 3 | 9,350 | Children's Oncology GroupNETWORK | 7 | May 28, 2026 | clinicaltrials |
| NCT01212926 | Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain(CA2D) | completed | N/A | 100 | University Hospital, BordeauxOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03106324 | A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant | completed | — | 911 | CelgeneINDUSTRY | 12 | May 28, 2026 | clinicaltrials |
| NCT03932643 | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | completed | Phase 1 | 20 | University of NebraskaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04640779 | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 22 | Mayo ClinicOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06026046 | Feasibility of an Adapted Sports Program Based on Fencing to Reduce Physical Deconditioning in Adult Hematology Patients(EscrimHEMA) | completed | N/A | 80 | University Hospital, AngersOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT00932412 | The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)(CLARA) | completed | Phase 2 | 735 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT01774630 | Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)(NiloPost-STIM) | completed | Phase 2 | 31 | University Hospital, BordeauxOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03434730 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03820817 | Rifaximin in Patients With Monoclonal Gammopathy | completed | Phase 1 | 50 | Emory UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04088864 | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | completed | Phase 1 | 10 | Kara Lynn DavisOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00690560 | Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma | completed | Phase 2 | 30 | Centre Antoine LacassagneOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01476410 | Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | completed | Phase 2 | 49 | Northwestern UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04915612 | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05534620 | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | completed | Phase 1 | 20 | medac GmbHINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06714370 | Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study(REVEAL) | completed | — | 24 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT02493530 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | completed | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT02949427 | The Oronasal Microbiota in Pediatric Oncology Patients | completed | — | 62 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04902833 | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | completed | — | 18 | Massachusetts General HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05032820 | Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | completed | Phase 2 | 40 | Medical College of WisconsinOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05564650 | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT02362997 | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04742101 | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 57 | Institut de Recherches Internationales ServierOTHER | 6 | May 18, 2026 | clinicaltrials |
| NCT05831787 | COVID19 OutcomeS in Myeloma and the Impact of VaCcines(COSMIC) | completed | — | 201 | ASH Research CollaborativeOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2026source: clinicaltrials